022100:KRXPOSCO DX COMPANY LTD. Analysis
Data as of 2026-06-15 - not real-time
₩28,650.00
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
Posco Dx is trading well above its 20‑day simple moving average but still below the 50‑day SMA, indicating a modest upward bias that is not yet strong enough to overcome a neutral trend. RSI sits near the mid‑range at 44, suggesting neither overbought nor oversold conditions, while the MACD line remains below its signal, delivering a bearish momentum signal. Volume has been increasing, supporting the price move, yet the stock exhibits extremely high 30‑day volatility (near 100%) and a beta above 1, pointing to heightened market sensitivity. Fundamentally, revenue has contracted by roughly 19% year‑over‑year and margins are thin (gross ~11%, operating ~1.5%), while the forward P/E of 51.6 sits well above the industry average of 38, flagging potential overvaluation. A discounted cash‑flow model values the company at about 12,600 KRW, far below the current price of 28,650 KRW, reinforcing the overvalued assessment. Although the dividend yield is modest (0.44%) and payout ratio sits at 55%, the balance sheet is strong with abundant cash and minimal debt, making the dividend sustainable.
Given the combination of bearish technical cues, weak top‑line growth, and a valuation gap, investors should approach Posco Dx cautiously. The high volatility and beta amplify downside risk, while the lack of compelling growth catalysts limits upside potential. In the near term, price pressure may intensify as the market reassesses the premium, but the solid cash position and low debt provide a cushion that could support a longer‑term hold if the company successfully pivots its technology offerings.
Given the combination of bearish technical cues, weak top‑line growth, and a valuation gap, investors should approach Posco Dx cautiously. The high volatility and beta amplify downside risk, while the lack of compelling growth catalysts limits upside potential. In the near term, price pressure may intensify as the market reassesses the premium, but the solid cash position and low debt provide a cushion that could support a longer‑term hold if the company successfully pivots its technology offerings.
Market Outlook
Short Term
< 1 yearCautious
Model confidence: 7/10
Key Factors
- Bearish MACD histogram
- Price still below resistance with limited upside
- Elevated short‑term volatility
Medium Term
1–3 yearsNeutral
Model confidence: 5/10
Key Factors
- Strong cash balance offsets earnings weakness
- Revenue contraction may stabilize with new digital contracts
- Dividend payout remains sustainable
Long Term
> 3 yearsCautious
Model confidence: 6/10
Key Factors
- Forward P/E far above industry peers
- DCF fair value indicates substantial downside
- Thin operating margins limit long‑term profitability
Key Metrics & Analysis
Financial Health
Revenue Growth-18.60%
Profit Margin3.38%
P/E Ratio51.6
ROE6.37%
ROA3.14%
Debt/Equity0.38
Op. Cash Flow₩134.8B
Free Cash Flow₩125.5B
Industry P/E38.2
Technical Analysis
TrendNeutral
RSI44.5
Support₩24,250.00
Resistance₩40,500.00
MA 20₩30,862.50
MA 50₩32,512.00
MA 200₩29,761.00
MACDBearish
VolumeIncreasing
Fear & Greed Index92.5
Valuation
Fair Value₩12,636.68
Target Price₩34,700.00
Upside/Downside21.12%
GradeOvervalued
TypeGrowth
Dividend Yield0.44%
Risk Assessment
Beta1.18
Volatility99.17%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.